Managing Director

Eric Cohen, MBA

Prior to founding Agile Capital Markets in early 2016, Eric COHEN served as CFO and executive in innovative healthcare and life science companies. His role was crucial as he managed to drive and finance the development of these companies. Eric was Teva Pharma France CFO (TEVA:NYSE) during the initiation of its generic business in France and the development of Copaxone (treatment of relapsing forms of multiple sclerosis).
Eric’s contribution was also notable within Hybrigenics (ALHYG:Euronext-Paris), a bio-pharmaceutical company with a focus on R&D of new targets and therapies against cancer, where he served as CFO and Deputy Managing Director and successfully led a private fund raising of 38 M€ and the company’s IPO on Euronext. His experience also covers medical devise business as CFO of Mauna Kea Technologies (MKEA:Euronext-Paris) pioneer in the endomicroscopy imaging, besides managing the company’s business in Germany and its global operations; Eric managed its IPO on Euronext (56 M€) and the follow-up offerings.
He currently serves as CFO of Acticor Biotech, a biotech company developing phase II treatment against acute ischemic stroke.
Eric earned a B.A and a M.A in Finance and Audit from Dauphine University in Paris and holds an MBA from London Business School.

Managing Director

Sophie Baratte, PhD, MBA

Sophie spent 20+ years in General Management roles in Blue chip companies and in Start-ups. As CEO, Sophie was CEO of CIT, the largest preclinical company in France, that she rebranded as Citoxlab, after acquiring additional businesses, and served as CEO of Cellnovo, developing and commercialising and e-connected insulin micro-pump. As CEO, Sophie raised around €80m and listed a company on Euronext in 2015. Amongst other key roles, Sophie served as GM for the in-vitro Diagnostics business of J&J France, as VP North EU for Sorin Group (now Livanova) across 5 BU in the cardiac sectors and Dialysis and as VP Sales and Marketing EU, Lifecell, in reconstructive Breast, Abdominal, Pelvic floor surgery. Along the years, Sophie has driven product development, industrialisation, market access and commercialisation in all geographies. Sophie’s education is Engineering in Biotechnology, PhD in Immunology and MBA.

Director Healthcare

Michael Khayat

Michael joined Agile Capital Markets as an intern in July 2020.
Prior to joining the firm, Michael graduated in Biotechnology Engineering from UTC and holds a Master of Science in Strategic Management from HEC Paris.
He is passionate about Life Sciences investments and entrepreneurship.

Associate Healthcare

Morgane Bonnevay

Morgane joined Agile in May 2021 as a Healthcare Analyst. She brings her dual background as a Pharmacist from Université de Paris and a Master in Management from ESSEC Business School. Prior to joining Agile, she contributed to the development of an innovative approached in neurology at Harvard Medical School and she developed her attract for innovation by working in a biotech company focused on organ on chip. She has also been the Founding President of JESP – Junior Etudes Santé Paris.

Senior Healthcare Analyst

Guillaume Colin

Guillaume joined Agile at the early beginning of 2021. He brings its dual background as a Pharmacist from Université de Lille and in Technology & Innovation Management from Université Paris Dauphine – PSL & MINES ParisTech.
Prior to joining Agile, he finetuned his analyst skills growing into the healthcare innovation field by means of several experiences in startups, CRO, Bio-incubator and an end-of-study internship at Merieux Equity Partners as VC Analyst.”

Healthcare Analyst

Pierre BERTIN

Pierre joined Agile in Avril 2022 as a Healthcare Analyst. He brings his dual background as a Pharmacist from Université Paris-Saclay and a Master of Sciences in Biopharmaceutical Management from ESCP Business School. 

Prior to joining Agile, he finetuned his analyst skills by means of several international experiences in startups and laboratories. He also developed medico-economics skills during his externship in the AGEPS (Agence Générale des Équipements et Produits de Santé) at AP-HP.

Healthcare Analyst

Steve-Maxence BENCHETRIT

Steve-Maxence joined Agile in November 2022, leveraging his diverse background as a Pharmacist from Université de Strasbourg and a Master’s in Management from EM Lyon Business School.

Before joining Agile, Steve-Maxence focused on enhancing his skills as an analyst in the field of healthcare innovation. He gained valuable experience through various positions, including serving as a VC Analyst at Andera Partners and Turenne Santé, and working as a Sell-Side Analyst at Portzamparc | BNP Paribas.

Advisor – Diabetes, Drugs & Tech, CPA & Audit

John Brooks

John L. Brooks III is the CEO and President of NeuroBo Pharmaceuticals, Inc., a Boston based natural products-based drug company advancing therapeutics for Diabetic Neuropathic Pain,

(Phase III) and for Alzheimer’s Disease (IND ready). Mr. Brooks is also the Managing Director of Healthcare Capital LLC, which advises early-stage life sciences companies. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations.

Mr. Brooks is the former President & Chief Executive Officer and Chairman of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization.

Mr. Brooks is a well-known life sciences executive. He has co-founded seven life sciences companies. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm.

Prior to that, Mr. Brooks was a senior medical device executive at Pfizer, and a senior manager at Arthur Andersen & Co. in Boston, MA, where he focused on early stage companies.

A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant.

Advisor – Cardiac, Dialysis

Michel Darnaud

Michel has built a successful career in key executive positions of blue chip MedTech firms. He served as President Europe at Baxter-Cardiovascular, as President Europe of Boston Scientific, before leading the global franchise of Cardiac Surgery at Livanova.
Michel also acted as Chairman of Eucomed and is now involved as Chairman and board member in several Innovative Life Sciences companies.
Michel has also developed a practice of Coaching for high level executives, providing mentoring and C-suite advice.

Advisor – Clinical, Regulatory, Quality, Market Access

Christophe Bailleul

Christophe Bailleul is currently acting as the VP Clinical and Regulatory Affairs, Head of QA at MedLumics. Christophe acted is the former Vice-President-Clinical Affairs at Mauna Kea Technologies SA and former Vice President-Clinical Affairs at St. Jude Medical France, Inc. Dr. Bailleul received an MBA, an undergraduate degree and a graduate degree from ESSEC Business School and an undergraduate degree from Université de Technologie de Compiègne.

Managing Partner & Founder – Orphéon Finance

James Palmer

James Palmer has 25 years of experience in investor relations and financial communications. He has worked for companies such as PSA Peugeot Citroën, Rhodia and Lafarge. Today, with his team, he advises and assists many companies of all sizes and in different sectors, industry, finance, biotech/medtech….whatever their strategic communication challenges are. He is a Director of the Franco British Chamber.